Catalan
Albanian
Arabic
Armenian
Azerbaijani
Belarusian
Bengali
Bosnian
Catalan
Czech
Danish
Deutsch
Dutch
English
Estonian
Finnish
Français
Greek
Haitian Creole
Hebrew
Hindi
Hungarian
Icelandic
Indonesian
Irish
Italian
Japanese
Korean
Latvian
Lithuanian
Macedonian
Mongolian
Norwegian
Persian
Polish
Portuguese
Romanian
Russian
Serbian
Slovak
Slovenian
Spanish
Swahili
Swedish
Turkish
Ukrainian
Vietnamese
Български
中文(简体)
中文(繁體)

anticancer/diarrea

L'enllaç es desa al porta-retalls
Pàgina 1 des de 2224 resultats

Cyclooxygenase-2 inhibition with celecoxib enhances antitumor efficacy and reduces diarrhea side effect of CPT-11.

Només els usuaris registrats poden traduir articles
Inicieu sessió / registreu-vos
Combining anticancer drugs with different mechanisms of action has the potential to enhance antitumor effect. CPT-11 (Camptosar, irinotecan), a topoisomerase I inhibitor, has been shown to be highly effective in the treatment of a variety of cancers. However, its clinical usage is often complicated

Optimal antidiarrhea treatment for antitumor agent irinotecan hydrochloride (CPT-11)-induced delayed diarrhea.

Només els usuaris registrats poden traduir articles
Inicieu sessió / registreu-vos
OBJECTIVE An antitumor camptothecin derivative CPT-11 has proven a broad spectrum of solid tumor malignancy, but its severe diarrhea has often limited its more widespread use. We have demonstrated from a rat model that intestinal beta-glucuronidase may play a key role in the development of

Management of cancer treatment-related diarrhea. Issues and therapeutic strategies.

Només els usuaris registrats poden traduir articles
Inicieu sessió / registreu-vos
The cancer treatment-related diarrhea caused by acute graft-versus-host disease (GVHD) and chemotherapeutic agents, particularly fluoropyrimidines and irinotecan, significantly affects patient morbidity and mortality. The mechanisms causing cancer treatment-related diarrhea are not fully understood,

The assessment and management of cancer treatment-related diarrhea.

Només els usuaris registrats poden traduir articles
Inicieu sessió / registreu-vos
Cancer treatment-induced diarrhea affects a high percentage of patients with cancer that receive chemotherapy or radiation treatment. Widely used criteria for measuring treatment-induced diarrhea, such as the National Cancer Institute Common Toxicity Criteria, do not account for important

[Diarrhea caused by systemic anti-cancer treatments].

Només els usuaris registrats poden traduir articles
Inicieu sessió / registreu-vos
Diarrhea is one of the most common complaints in oncologic patients. Causes are multiple including bowel resection, infections, radiation and systemic anti-cancer treatments. In the latter case, the pathophysiology is partially elucidated and requires the etiology to be precisely identified :

Cancer treatment-induced diarrhea: interventions to minimize the roller coaster ride.

Només els usuaris registrats poden traduir articles
Inicieu sessió / registreu-vos
This program used a case-study approach to discuss interventions that nurses can implement in their daily clinical environment to minimize cancer treatment-induced diarrhea. Manifestations of cancer treatment-induced diarrhea, medical treatment options, and nutritional interventions were covered.
OBJECTIVE Randomized studies have suggested that sucralfate is effective in mitigating diarrhea during pelvic radiation therapy (RT). This North Central Cancer Treatment Group study was undertaken to confirm the antidiarrheal effect of sucralfate. Several other measures of bowel function were also
Irinotecan (CPT-11), a first-line chemotherapy for advanced colorectal cancer, causes serious diarrhea in patients receiving treatment. The underlying mechanism has been shown that the active metabolite of CPT-11, SN-38, is metabolized to the inactive metabolite SN-38 glucuronide (SN-38 G) during
OBJECTIVE To evaluate and compare the influence of dietary elements on cancer progression, chemotherapy efficacy, and toxicity, particularly severe, late-onset diarrhea related to irinotecan (CPT-11) treatment. METHODS We used laboratory rats fed a standardized basal diet, Ward colon tumor, and

Recommended guidelines for the treatment of cancer treatment-induced diarrhea.

Només els usuaris registrats poden traduir articles
Inicieu sessió / registreu-vos
OBJECTIVE To update and expand on previously published clinical practice guidelines for the treatment of cancer treatment-induced diarrhea. METHODS An expert multidisciplinary panel was convened to review the recent literature and discuss recommendations for updating the practice guidelines

Octreotide long-acting formulation (LAR) in chronic loperamide-refractory diarrhea not related to cancer treatment.

Només els usuaris registrats poden traduir articles
Inicieu sessió / registreu-vos
OBJECTIVE The effectiveness and improvement in quality of life (QOL) of a long-acting formulation of octreotide (LAR) administration for cancer patients, with chronic loperamide-refractory diarrhea not attributed to medical therapy, were investigated. METHODS Twenty-nine patients with chronic
OBJECTIVE To assess the effectiveness of depot octreotide for the prevention of diarrhea during pelvic radiation therapy. METHODS Patients receiving pelvic radiation therapy (planned minimum dose, 45 Gy; 1.7 to 2.1 Gy daily) were eligible for the study. From May 10, 2002, through October 14, 2005,

[Management of cancer treatment-related diarrhea and constipation].

Només els usuaris registrats poden traduir articles
Inicieu sessió / registreu-vos
Digestive complications are frequent dose-limiting side-effect of chemotherapy. Diarrhea and constipation can affect quality of life and alter optimum treatment efficacy. The incidence and the severity of these toxicities have to be systematically evaluated in order to provide specific curative and

New strategies for the prevention and reduction of cancer treatment-induced diarrhea.

Només els usuaris registrats poden traduir articles
Inicieu sessió / registreu-vos
OBJECTIVE To describe possible new strategies for the prevention of CTID. METHODS Abstracts presented at oncology meetings, primary and secondary literature, trial protocols, and clinical experience. CONCLUSIONS Patients who have experienced an episode of diarrhea are at high risk for developing

Management of acute cancer treatment-induced diarrhea.

Només els usuaris registrats poden traduir articles
Inicieu sessió / registreu-vos
OBJECTIVE To describe the dietary and pharmacologic management of acute CTID. METHODS Primary and secondary literature, and clinical experience. CONCLUSIONS When dietary strategies do not work, or when patients present with grade 3/4 diarrhea, pharmacologic intervention is required. First-line
Uneix-te a la nostra
pàgina de Facebook

La base de dades d’herbes medicinals més completa avalada per la ciència

  • Funciona en 55 idiomes
  • Cures a base d'herbes recolzades per la ciència
  • Reconeixement d’herbes per imatge
  • Mapa GPS interactiu: etiqueta les herbes a la ubicació (properament)
  • Llegiu publicacions científiques relacionades amb la vostra cerca
  • Cerqueu herbes medicinals pels seus efectes
  • Organitzeu els vostres interessos i estigueu al dia de les novetats, els assajos clínics i les patents

Escriviu un símptoma o una malaltia i llegiu sobre herbes que us poden ajudar, escriviu una herba i vegeu malalties i símptomes contra els quals s’utilitza.
* Tota la informació es basa en investigacions científiques publicades

Google Play badgeApp Store badge